HAIFA, Israel, July 27 th, 2021 – MeMed, a leader in host response-based technologies, today announces that it has received the CE Mark in Europe for its new disease management solution, MeMed ...
—First Multi-Center Randomized Controlled Clinical Trial in the US to Show MeMed BV's Impact on Reducing Unnecessary Antibiotics, Supporting Clinical Decision-Making— — Preliminary Data Analysis ...
HAIFA, Israel, June 2, 2020 – MeMed Ltd., a leader in host response-based solutions, today announced that it has received a CE Mark in Europe for use of its diagnostic test MeMed BV™ and point-of-need ...
-MeMed BV Flex™ simultaneously measures multiple host proteins, paired with machine learning, to deliver highly accurate results in 15 minutes from just a few drops of blood- -Designed for use in ...
MeMed, a medtech company focused on translating the immune system’s complex signals into simple insights that transform how diseases are diagnosed and treated, today announced that FDA has granted ...
MeMed’s BV test, which will be commercialized with DiaSorin, was developed along with academic centers and commercial partners and is backed by data from over 15,000 patients. Multinational, ...
MeMed Completes Trilogy of Clinical Studieswith More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections MeMed today announced ...
FDA Grants Breakthrough Device Designation to MeMed Severity Test for Patients with Suspected Sepsis
-Major Development Milestone Reinforces MeMed’s Leadership in Host-Response Diagnostics- -FDA Endorsement Accelerates Product Development and Market Readiness- ANDOVER, Mass. & HAIFA, Israel–(BUSINESS ...
Opens up testing to decentralized settings including urgent care centers which see 100 million patient visits for potential infections in the US annually Significant milestone towards making bacterial ...
ANDOVER, Mass. & HAIFA, Israel--(BUSINESS WIRE)--MeMed, a leader in host-response diagnostics, today announced the addition of three distinguished experts to its advisory board to accelerate its ...
MeMed Diagnostics, a Haifa-based firm that develops diagnostic solutions to monitor the body’s immune state, has received United States Food and Drug Administration (FDA) 510(k) clearance for a test ...
Israeli diagnostics player MeMed reported data from a study of more than 500 children and adolescents showing that its blood test can accurately tell the difference between a bacterial and a viral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback